CCPA led a sign-on letter, in partnership with the HIV+Hep Policy Institute, outlining concerns with a provision included in the 2021 Notice of Benefit and Payment Parameters (NBPP) that would allow insurers to exclude cost-sharing assistance from counting towards patients’ out-of-pocket maximums. The change could result in significant cost increases for patients that could prevent access to critical medications.
Ultimately, over 100 advocacy organizations from across the country joined together to urge Congress to pass legislation to delay the implementation of this rule for at least a year and in the interim, reinstate the limitations on copay accumulators included in the 2020 NBPP. This delay will prevent this rule from harming patients during our ongoing public health emergency and provide additional time to evaluate the impact accumulator adjustment programs have on patients.
We would like to thank all of the co-signers who joined us in advocating for patient access to prescription medication. CCPA will continue to engage on this issue throughout the year, and will make sure to keep all of our partners updated on our future efforts.
You can download the letter here.
If you have any questions, please contact Liz Helms, Director, CCPA, email@example.com.